Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | WRN | Q14191 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049984 | 0.78 | GSK3A (0.50) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL29995038 | 0.77 | GSK3A (0.48) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL16590557 | 0.77 | ALDH1A1 (0.46) | GSK3AGSK3BALDH1A1MAPTLMNA | |
| SCHEMBL22923642 | 0.76 | PTGS1 (0.58) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL22281365 | 0.75 | GSK3A (0.47) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL8738193 | 0.74 | GSK3A (0.46) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL437306 | 0.74 | GSK3A (0.50) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL19545832 | 0.71 | GSK3A (0.47) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL3665093 | 0.71 | GSK3A (0.52) | GSK3AGSK3BMGLLALDH1A1MAPT | |
| SCHEMBL28353956 | 0.70 | GSK3A (0.50) | GSK3AGSK3BMGLLALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338564-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (FR) | 2023-10-26 | — | — | US | disclosed |
| US-20160220694-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058064-A1 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130184435-A1 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8465724-B2 | Multi-drug ligand conjugates | ENDOCYTE, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184435-A1 | MULTI-DRUG LIGAND CONJUGATES | VDR, CD44, HCAR1 | GSK3A 4360/4885GSK3B 4133/4885MGLL 3100/4885 |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | GSK3A 3790/4885GSK3B 3355/4885MGLL 3107/4885 |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | GSK3A 3868/4885GSK3B 3514/4885MGLL 4525/4885 |
| US-20160220694-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | GSK3A 3906/4885GSK3B 3561/4885MGLL 2839/4885 |
| US-20140058064-A1 | MULTI-DRUG LIGAND CONJUGATES | VDR, CD44, HCAR1 | GSK3A 4360/4885GSK3B 4133/4885MGLL 3100/4885 |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | GSK3A 3790/4885GSK3B 3355/4885MGLL 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.